NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
Charles River
»15/04/2010 [Company watch]
Charles River Shanghai preclinical facility receives Belgian GLP cert

Charles River Shanghai Receives OECD Certification. First preclinical contract research organization in China to receive certification

Charles River Laboratories, Inc. (NYSE: CRL), today announced the Company’s Shanghai facility became the first preclinical laboratory in China to receive a Certificate of Good Laboratory Practice (GLP) compliance from an Organization for Economic Cooperation and Development (OECD) member country. The certificate acknowledges the site is operating in compliance with OECD Principles of GLP for both toxicology and laboratory services. The one-week inspection was conducted by the Belgian national GLP compliance monitoring authority. In addition to an extensive facility assessment, the inspection included an audit of three completed and two on-going studies. The facility inspection evaluated key operations areas including: vivarium rooms, pharmacy, analytical chemistry, bioanalytical chemistry, clinical pathology, and histopathology. After a thorough audit of the facility, the Belgian national GLP compliance monitoring authority certified that Charles River’s Shanghai facility is operating in compliance with OECD Principles of Good Laboratory Practice. “The facility has best practices in place for conducting GLP studies which are supported by sophisticated systems and a well organized site,” said Mr. Guido Jacobs, GLP Inspector, Belgium Government Scientific Institute of Public Health, Bureau of Quality Assurance. “Our China facility was established on the premise that we would provide our clients with the same high standards of research, safety, animal welfare and good laboratory practices that distinguish Charles River,” said James C. Foster, Chairman, President and Chief Executive Officer of Charles River. “As the first preclinical CRO to receive a Certificate of Compliance from an OECD member country, Charles River is distinctively positioned to help our clients develop IND-enabling programs at our Shanghai facility. This certification marks a significant milestone in our commitment to strategically partner with our clients globally to accelerate their drug development programs.” Charles River’s Shanghai facility has also received accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), the Canadian Council on Animal Care (CCAC) and the Shanghai Laboratory Animal Commission (SLAC). Additional details of these regulatory milestones are outlined in the press release “Charles River Shanghai Facility Receives AAALAC, CCAC and SLAC Accreditations.”

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.